PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of nihpaAbout Author manuscriptsSubmit a manuscriptHHS Public Access; Author Manuscript; Accepted for publication in peer reviewed journal;
 
Ann Neurol. Author manuscript; available in PMC 2012 April 1.
Published in final edited form as:
Published online 2010 November 29. doi:  10.1002/ana.22271
PMCID: PMC3155276
NIHMSID: NIHMS239015

Plasma EGF levels predict cognitive decline in Parkinson's Disease

Abstract

Objective

Most people with Parkinson's disease (PD) eventually develop cognitive impairment (CI). However, neither the timing of onset nor the severity of cognitive symptoms can be accurately predicted. We sought plasma-based biomarkers for CI in PD.

Methods

A discovery cohort of 70 PD patients was recruited. Cognitive status was evaluated with the Mattis Dementia Rating Scale-2 (DRS) at baseline and on annual follow-up visits, and baseline plasma levels of 102 proteins were determined with a bead-based immunoassay. Using linear regression, we identified biomarkers of CI in PD, i.e. proteins whose levels correlated with cognitive performance at baseline and/or cognitive decline at follow-up. We then replicated the association between cognitive performance and levels of the top biomarker, using a different technical platform, with a separate cohort of 113 PD patients.

Results

Eleven proteins exhibited plasma levels correlating with baseline cognitive performance in the discovery cohort. The best candidate was epidermal growth factor (EGF, p<0.001); many of the other 10 analytes co-varied with EGF across samples. Low levels of EGF not only correlated with poor cognitive test scores at baseline, but also predicted an eightfold greater risk of cognitive decline to dementia-range DRS scores at follow-up for those with intact baseline cognition. A weaker, but still significant, relationship between plasma EGF levels and cognitive performance was found in an independent replication cohort of 113 PD patients.

Interpretation

Our data suggest that plasma EGF may be a biomarker for progression to CI in PD.

Keywords: Epidermal growth factor, EGF, Parkinson's Disease, Parkinson's Disease with Dementia, Biomarker, Plasma

INTRODUCTION

Parkinson's disease (PD) is a common neurodegenerative disease affecting dopaminergic neurons of the substantia nigra, resulting in symptoms of bradykinesia, rigidity, and tremor. Over time, however, the disease process spreads throughout many brain regions,1 and cognitive symptoms almost inevitably develop.2,3, 4 Indeed, up to 83% of PD patients develop dementia during their disease course.3-5

The development of PD with dementia (PDD) or cognitive impairment (CI) is a significant transition for patients and families,6 and adds to the cost of care,7 yet its occurrence is unpredictable.8 While clinical measures9, 10 and genotype at the apolipoprotein E gene (APOE)11 or microtubule associated protein tau gene (MAPT)12 may be broadly informative of the risk of developing CI in PD, and PDD may demonstrate reduced CSF levels of Aβ1-42 (Siderowf et al, in press),13 a plasma-based biomarker for the risk of CI or dementia in PD, usable at the individual level, is urgently needed.

In the present study, we evaluated levels of 102 plasma-based proteins for correlation to cognitive performance at baseline and over a median follow-up period of 21 months. We identified 11 potential biomarkers of CI in PD, with epidermal growth factor (EGF) demonstrating the most robust signal. Strikingly, low EGF levels were also predictive of a greatly increased risk of conversion to PDD-range cognition during follow-up and may implicate EGF in a new pathway in the development of dementia in PD.

METHODS

Plasma sampling and biomarker quantitation

For the discovery set, 70 patients aged 60 years or older with a diagnosis of idiopathic PD based on British Brain Bank criteria14 were recruited to the University of Pennsylvania (UPenn) Udall Center without bias towards high or low cognitive function, with the exception that subjects meeting criteria for dementia with Lewy bodies (DLB)15 were excluded. For the replication set, 113 additional patients were subsequently recruited in the same manner as the discovery set (next consecutive recruits to our study center). Whole blood samples from all patients were obtained under IRB approval (EDTA 10.8mg, 5mL tubes), placed immediately on ice, spun down for plasma aliquotting (3000rpm, 5min, 4°C, 0.5mL aliquots), and frozen at −80°C within the same day. Plasma aliquots were then stored at −80°C until analysis. Collection site and specimen processing were uniform for all samples in both patient cohorts.

Simultaneous screening of 151 proteins by multiplex immunoassay on the Human DiscoveryMAP panel using a Luminex100 platform was then performed for discovery cohort samples, in one batch, by Rules-Based Medicine, Inc. (RBM, Austin, TX), as previously described,16 and reviewed recently (Hu et al., in press). Additional details are available from RBM (http://www.rulesbasedmedicine.com) and in supplementary methods. Of the 151 proteins in the RBM Human DiscoveryMAP panel, 102 proteins passed our quality control measures (<20% of samples below lowest reliable value as given by RBM, <40% coefficient of variation (CV) across technical triplicates) and were used (see Supplementary Table 1).

For confirmation of EGF values, separate aliquots of samples previously run on the multiplex immunoassay were quantified on an EGF enzyme-linked immunosorbent assay (ELISA, R&D Systems, Minneapolis, MN). The same ELISA assay was used to measure plasma EGF levels in the replication cohort.

Cognitive tests

The Mattis Dementia Rating Scale-2 (DRS)17 was used to evaluate cognition in study patients.18,19,20,21 A raw score was obtained and adjusted for age as previously described.22 We used an age-adjusted score cut-off of ≤5 for cognitive performance in the PDD range, following recommended criteria in the DRS manual,17 also validated in PD patients.19 All subjects had baseline DRS testing within 6 months of plasma draw; 61/70 subjects had DRS testing on the same day as the plasma draw – the 9 individuals who were tested on a different day fell into all 4 quartiles of EGF values. 61/70 subjects had subsequent DRS testing during a median follow-up of 21 months.

APOE genotyping

DNA was extracted from EDTA blood samples using commercial reagents (FlexiGene, Qiagen, Valencia, CA). Two single nucleotide polymorphisms (SNPs) (rs7412 and rs429358) in APOE were genotyped using allelic discrimination assays with TaqMan reagents (Applied Biosystems, Foster City, CA) on an ABI 7500. The APOE genotypes (ε2, ε3, and ε4) were assigned by incorporating the genotyping results from both SNPs into an algorithm.

Statistical analyses

Linear regression analyses evaluating the association of levels of each protein to age-adjusted DRS scores were performed in R. Full details are in supplementary methods. In brief, the model used for discovery screening designated age and gender as covariates and evaluated the association of each protein individually to DRS scores. For the top 11 proteins, we further evaluated the association between each protein and the DRS score in models incorporating additional covariates such as UPDRS motor score or disease duration since these factors are known to be associated with cognitive impairment. Of note, for EGF, our top analyte, the best multivariate model by a forward stepwise approach designated EGF as the independent variable, age-adjusted DRS as the dependent variable, and age and sex as covariates with no interaction terms. Hence, this was used as the final model for the discovery set. In addition, for EGF, we performed secondary analyses incorporating medications (as yes/no categorical factors) and APOE genotype as covariates to evaluate whether these factors affected the association between EGF levels and cognitive performance.

The Partek Genomics Suite was used to perform hierarchical cluster analysis (Euclidean distance) of co-expression among the top 11 proteins, and to generate graphics (Partek GS, copyright 2010, St. Louis, MO). Survival curves were compared with log-rank tests. To evaluate the effects of baseline DRS performance, age, and gender on the relationship between EGF quartile and conversion to PDD-range DRS, Cox proportional hazards models were used. All statistical tests were two-sided.

In the replication cohort, as in the discovery cohort, linear regressions were used to evaluate the relationship between DRS performance and EGF levels, as well as other potential variables (age, sex, UPDRS motor score) affecting cognitive performance. A forward stepwise approach was again used to determine the final multivariate model with EGF specified as the independent variable, age-adjusted DRS as the dependent variable, and age, sex, UPDRS motor score, and their interaction terms as possible covariates. The final model, with an R2 value of 0.28, incorporated sex, UPDRS motor score, EGF, and their interaction terms. An alternative model substituting Hoehn and Yahr stage for UPDRS motor score performed similarly.

RESULTS

Study cohorts

70 PD patients were used in the discovery phase of the study, and 113 patients were used in the replication phase, with the total 183 patients representing consecutive study recruits. In the initial cohort of 70, 16 (23%) had cognitive scores within the PDD-range (age-adjusted DRS≤5), and 54 did not (age-adjusted DRS>5); age, gender, age at disease onset, disease duration, UPDRS motor scores, use of dopaminergic agents, and APOE genotypes were similar between these two groups (Table 1).

Table 1
Clinical features of Parkinson's patients with (DRS≤5) and without (DRS>5) significant cognitive impairment

In the replication cohort, 13/113 (12%) had PDD-range cognitive scores. Unlike in the discovery cohort, in this case, the PDD-range individuals were more likely to be male (p=0.016), significantly older (p=0.029), with a longer disease duration (p=0.002) and higher UPDRS motor scores (p=0.023) than the non-demented individuals. They were also less likely to be on dopamine agonists (p=0.002); use of levodopa and APOE genotypes were similar to non-demented individuals (Table 1).

Identification of biomarkers for cognitive impairment in PD

Using our discovery cohort, we evaluated levels of 102 proteins individually for correlation with age-adjusted DRS, using linear regression in a model adjusting for age and gender. Eleven proteins showed correlations between plasma levels and DRS score (p<0.05), with EGF (p<0.001) and CD40 ligand (p=0.006) demonstrating the most significant associations (Table 2). Moreover, most of these 11 proteins co-varied across samples (Figure 1), with EGF, CD40 ligand, thrombospondin-1, PAI-1, and PDGF forming one cluster with particularly correlated expression (Figure 1). In addition, the association between cognitive test performance and plasma protein levels persisted for EGF, CD40 ligand, and heparin-binding EGF (HBEGF) in models that accounted for either disease duration or UPDRS-motor scores, in addition to age and gender (Table 2). Interestingly, HBEGF expression was not correlated with EGF expression, despite both demonstrating relationships with cognition, implying differential regulation of these two proteins. Finally, plasma levels of the soluble receptors for EGF and CD40 ligand – EGF receptor (EGF-R) and CD40 – were neither associated with DRS scores, nor correlated with expression of their ligands (Table 2, Figure 1).

Figure 1
Expression of proteins with plasma levels associated with cognitive performance
Table 2
11 plasma proteins with levels significantly associated with baseline cognitive performance

Plasma EGF as a candidate biomarker for cognitive impairment in PD

Following this initial screen, we focused on EGF as the top analyte correlated with cognitive performance in PD. Accordingly, we further investigated aspects of EGF as a candidate biomarker for CI in PD. To do this, we used an enzyme linked immunosorbent assay (ELISA) to measure plasma EGF levels on 24 samples from our discovery cohort with same-day duplicate plasma aliquots. Cross-platform correlation of EGF levels by ELISA was excellent across the 24 samples (r2 0.76, Figure 2a), indicating that EGF is technically robust as a biomarker for CI in PD.

Figure 2
EGF as a biomarker for cognitive impairment in PD

In the initial analyses, DRS scores were treated as a continuous variable. Dichotomizing scores into PDD-range (age-adjusted DRS≤5) and non-PDD-range (age-adjusted DRS>5), we evaluated whether levels of our top plasma analyte (EGF) could serve as a classifier for PDD-range DRS. However, trade-offs between specificity and sensitivity limited the utility of EGF as a classifying biomarker for baseline PDD-range performance, with a maximum classification accuracy of 79%.

Plasma EGF levels predict cognitive decline in PD

Follow-up DRS testing was available for 61/70 discovery samples, with a median follow-up of 21 months and interquartile range (IQR) of 13-26 months. We next determined if baseline EGF levels predicted conversion from non-PDD-range DRS scores to PDD-range DRS scores (i.e. ≤5) among subjects with age-adjusted DRS scores>5 at baseline. Strikingly, survival analyses of time to PDD-range showed markedly different outcomes for those subjects with the lowest plasma EGF levels (Figure 2b). Specifically, non-PDD-range subjects with EGF levels in the lowest quartile (Quartile 1, Figure 2c) were eight times more likely to convert to PDD-range, with a median conversion time of 14 months (p<0.001, hazard ratio 8.34, 95% CI 4.26-122.90). The other three quartiles of EGF levels did not differ significantly from each other (Figure 2b). The association between EGF quartile and risk for conversion persisted in models adjusting for age and baseline DRS score (p=0.033 for EGF quartile, hazard ratio 4.95, 95% CI 1.14-21.74, Supplementary Figure 1); or age, gender, and baseline DRS score (p=0.037 for EGF quartile, hazard ratio 4.88, 95% CI 1.10-21.74).

APOE genotype and medications do not affect the association between EGF levels and cognitive performance

We next analyzed the effects of specific medications (levodopa, dopamine agonists, antipsychotic medications, anti-depressant medications, statins, cholinesterase inhibitors, memantine, and benzodiazepines) and APOE genotype on our findings. We found no effect of these variables on the association between EGF levels and DRS performance (Table 3).

Table 3
Relationship between cognitive performance and EGF plasma values is not affected by medications or ApoE genotype

Correlation of plasma EGF levels and cognitive performance persists in a replication cohort

To add confidence to our finding of a correlation between EGF levels and cognitive performance in the discovery cohort, we recruited an additional 113 PD patients, measured plasma EGF levels by ELISA, and tested cognitive performance with the DRS. While there were significant, unforeseen, differences in the clinical characteristics of this second cohort, the correlation between plasma EGF levels and age-adjusted DRS scores persisted (p=0.035), with the same directionality. In the replication cohort, both gender and degree of motoric impairment (as reflected in UPDRS motor score) were significantly associated with cognitive performance, and the best multivariate model included these two factors, as well as interaction terms, with EGF levels as predictors of age-adjusted DRS score (Figure 3).

Figure 3
Correlation of plasma EGF and age-adjusted DRS score in an independent replication cohort

DISCUSSION

In the present study, we evaluated cognitive performance and plasma levels of 102 proteins in an initial discovery cohort of 70 PD patients. We identified 11 potential biomarkers of CI in PD, with EGF as our top biomarker, showing promise as a predictor of cognitive decline in PD. We then replicated the association between plasma EGF levels and cognitive performance in a separate cohort of 113 PD patients, using a different technical platform for measuring EGF.

Plasma EGF demonstrates several characteristics that make it attractive as a biomarker for CI in PD. First, as shown in our cross-platform comparison and use of two different technical assays in the discovery and replication cohorts, measurement of EGF levels is robust to differing assay techniques. Second, despite demographic and clinical differences between our discovery and replication cohorts, the relationship between plasma EGF levels and cognitive performance persisted. This last point may be particularly important, as many potential biomarkers fail to replicate in follow-up studies, presumably due to the considerable “noisiness” of clinical data, which leads to both false positives and false negatives.

In addition, the fact that plasma EGF levels have potential for serving as a predictor of cognitive decline in PD has both practical and mechanistic implications. On a practical level, such a predictive biomarker might prove quite useful in identifying at-risk populations for clinical intervention with trial therapeutic agents. On a mechanistic level, the fact that EGF levels are low in PD with CI and in PD at highest risk of developing CI suggests that EGF pathways may be implicated mechanistically in the development of CI and dementia in PD. Indeed, EGF has been reported as a neurotrophic factor supporting both adult subventricular zone neurons23 and midbrain dopaminergic neurons24 in models of PD and in human PD patients. Moreover, EGF-R signaling pathways may regulate the survival of midbrain dopaminergic neurons in PD models.25 In our study, levels of both EGF and HBEGF – another protein reported to support dopaminergic neurons26 – were correlated with cognitive function; yet expression levels of these two proteins were not correlated with each other across samples. This finding suggests that the effect observed (1) may be mediated by EGF-R, for which both EGF and HBEGF can serve as ligands, and (2) is not due to a confounder, which might be expected to affect EGF levels and HBEGF levels similarly across cases. It should be noted that while EGF-R levels measured in this study were not correlated with cognitive performance, our method would only quantify circulating EGF-R, which may not reflect levels of cell-bound receptor.

Given the association between plasma EGF levels and DRS scores, why was EGF not a better classifier for baseline cognition? Close scrutiny of patterns of EGF expression in our cohort reveals that many samples mis-classified (using low EGF levels) as falling into the PDD-range in fact “convert” to PDD-range cognitive performance in the follow-up period (Figure 1, green arrows). Thus, the very fact that low EGF levels are predictive of future cognitive decline may hamper utility as a classifying biomarker for baseline cognition. The implication of this observation is that low EGF levels precede the development of dementia in PD and that EGF signaling may be involved mechanistically in progression of cognitively normal PD patients to PDD.

Our replication cohort differed in several important ways from our discovery cohort. Both cohorts were recruited in the same manner, to the same center, as consecutive study subjects; their differences may reflect characteristics of patients more likely to join a research study earlier vs. later. In any case, the relationship between plasma EGF and cognition was observed in both cohorts. It is worth noting, however, that the correlation only achieved statistical significance in the latter cohort after accounting for effects from gender and motoric impairment. While it is certainly possible that this is due to Type I error in our discovery cohort, the more likely interpretation is that thorough analysis of effects of other factors on cognition in PD will be needed in follow-up studies, given the considerable variation among human subjects.

Several caveats should be considered in interpreting our results. First, while we were able to replicate the cross-sectional association between EGF levels and cognitive performance, follow-up in the replication cohort (recruited after the discovery cohort) has been too short to assess whether the finding of low EGF levels as predictive of cognitive decline is also seen. Thus, future studies evaluating more PD patients with long follow-up periods would be a valuable addition to the data presented here.

One question that arises from our current study is whether the correlation between low EGF levels and poor cognitive performance is specific to PD. While a thorough consideration of this question is outside the scope of this study, we found no association between EGF levels and APOE genotype, a risk factor for Alzheimer's Disease (AD), and we have not found EGF levels to differ significantly between AD patients and normal controls in CSF,27 or in plasma (manuscript in prep).

In summary, we used an unbiased screen of 102 proteins to identify potential biomarkers for CI in PD. Eleven proteins emerged from our screen, many showing co-expression with the top analyte, EGF. The correlation between plasma EGF levels and cognitive performance replicated in an additional cohort of 113 patients, on a different technical platform. Finally, low levels of EGF were predictive of an eightfold greater risk of conversion from non-PDD-range cognitive performance to PDD-range cognitive performance, with a median time-to-conversion of 14 months.

While some studies have reported CSF biomarkers as potential indicators of risk for development of PDD,13 to our knowledge, the current result is the first plasma-based, non-genetic risk factor for CI in PD. If confirmed by further studies, the measurement of EGF levels may be useful both as a clinical diagnostic tool and in the design of trials aimed at preserving cognition in PD. With PD affecting more than 500,000 individuals in the US alone, and prevalence projected to double in the next 25 years,5 the need for such tools cannot be overstated.

Supplementary Material

Supp App

Supp Fig s1 & Table s1

ACKNOWLEDGEMENTS

We thank the many patients who contributed samples for this study. We thank Sue Leight, Travis Unger, and Emily Ashbridge for technical assistance and Jason Karlawish for helpful comments. This work was supported by the Penn-Pfizer Alliance as well as funding from the NIH (AG033101, AG10124, AG17586, AG024904, NS-053488), and the Marian S. Ware Alzheimer Program. ASCP is additionally supported by a Burroughs Wellcome Fund Career Award for Medical Scientists and the Benaroya Fund. WTH and RGG are supported by Clinical Translational Research Fellowships from the American Academy of Neurology. HDS is an employee of Pfizer Global Research and Development. VMYL is the John H. Ware, 3rd, Professor of Alzheimer's Disease Research. JQT is the William Maul Measey-Truman G. Schnabel, Jr., Professor of Geriatric Medicine and Gerontology.

REFERENCES

1. Braak H, Del Tredici K, Rub U, et al. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging. 2003;24:197–211. [PubMed]
2. Williams-Gray CH, Foltynie T, Brayne CE, et al. Evolution of cognitive dysfunction in an incident Parkinson's disease cohort. Brain. 2007;130:1787–1798. [PubMed]
3. Hely MA, Reid WG, Adena MA, et al. The Sydney multicenter study of Parkinson's disease: the inevitability of dementia at 20 years. Mov Disord. 2008;23:837–844. [PubMed]
4. Buter TC, van den Hout A, Matthews FE, et al. Dementia and survival in Parkinson disease: a 12-year population study. Neurology. 2008;70:1017–1022. [PubMed]
5. Mayeux R, Denaro J, Hemenegildo N, et al. A population-based investigation of Parkinson's disease with and without dementia. Relationship to age and gender. Arch Neurol. 1992;49:492–497. [PubMed]
6. Aarsland D, Larsen JP, Karlsen K, et al. Mental symptoms in Parkinson's disease are important contributors to caregiver distress. Int J Geriatr Psychiatry. 1999;14:866–874. [PubMed]
7. Pressley JC, Louis ED, Tang MX, et al. The impact of comorbid disease and injuries on resource use and expenditures in parkinsonism. Neurology. 2003;60:87–93. [PubMed]
8. Leverenz JB, Quinn JF, Zabetian C, et al. Cognitive impairment and dementia in patients with Parkinson disease. Curr Top Med Chem. 2009;9:903–912. [PMC free article] [PubMed]
9. Uc EY, Rizzo M, Anderson SW, et al. Visual dysfunction in Parkinson disease without dementia. Neurology. 2005;65:1907–1913. [PubMed]
10. Levy G, Jacobs DM, Tang MX, et al. Memory and executive function impairment predict dementia in Parkinson's disease. Mov Disord. 2002;17:1221–1226. [PubMed]
11. Huang X, Chen P, Kaufer DI, et al. Apolipoprotein E and dementia in Parkinson disease: a meta-analysis. Arch Neurol. 2006;63:189–193. [PubMed]
12. Goris A, Williams-Gray CH, Clark GR, et al. Tau and alpha-synuclein in susceptibility to, and dementia in, Parkinson's disease. Ann Neurol. 2007;62:145–153. [PubMed]
13. Mollenhauer B, Trenkwalder C, von Ahsen N, et al. Beta-amlyoid 1-42 and tau-protein in cerebrospinal fluid of patients with Parkinson's disease dementia. Dement Geriatr Cogn Disord. 2006;22:200–208. [PubMed]
14. Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry. 1992;55:181–184. [PMC free article] [PubMed]
15. McKeith IG, Dickson DW, Lowe J, et al. Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology. 2005;65:1863–1872. [PubMed]
16. Spina S, Murrell JR, Huey ED, et al. Corticobasal Syndrome Associated With the A9D Progranulin Mutation. J Neuropathol Exp Neurol. 2007;66:892–900. [PubMed]
17. Jurica PJ, L S, Mattis S, editors. Dementia Rating Scale-2 (DRS-2): Professional Manual: Psychological Assessment Resources. 2001
18. Llebaria G, Pagonabarraga J, Kulisevsky J, et al. Cut-off score of the Mattis Dementia Rating Scale for screening dementia in Parkinson's disease. Mov Disord. 2008;23:1546–1550. [PubMed]
19. Aarsland D, Litvan I, Salmon D, et al. Performance on the dementia rating scale in Parkinson's disease with dementia and dementia with Lewy bodies: comparison with progressive supranuclear palsy and Alzheimer's disease. J Neurol Neurosurg Psychiatry. 2003;74:1215–1220. [PMC free article] [PubMed]
20. Reyes MA, Lloret SP, Gerscovich ER, et al. Addenbrooke's Cognitive Examination validation in Parkinson's disease. Eur J Neurol. 2009;16:142–147. [PubMed]
21. Dubois B, Burn D, Goetz C, et al. Diagnostic procedures for Parkinson's disease dementia: recommendations from the movement disorder society task force. Mov Disord. 2007;22:2314–2324. [PubMed]
22. Lucas JA, Ivnik RJ, Smith GE, et al. Normative data for the Mattis Dementia Rating Scale. J Clin Exp Neuropsychol. 1998;20:536–547. [PubMed]
23. O'Keeffe GC, Tyers P, Aarsland D, et al. Dopamine-induced proliferation of adult neural precursor cells in the mammalian subventricular zone is mediated through EGF. Proc Natl Acad Sci U S A. 2009;106:8754–8759. [PubMed]
24. Iwakura Y, Piao YS, Mizuno M, et al. Influences of dopaminergic lesion on epidermal growth factor-ErbB signals in Parkinson's disease and its model: neurotrophic implication in nigrostriatal neurons. J Neurochem. 2005;93:974–983. [PubMed]
25. Inoue H, Lin L, Lee X, et al. Inhibition of the leucine-rich repeat protein LINGO-1 enhances survival, structure, and function of dopaminergic neurons in Parkinson's disease models. Proc Natl Acad Sci U S A. 2007;104:14430–14435. [PubMed]
26. Farkas LM, Krieglstein K. Heparin-binding epidermal growth factor-like growth factor (HB-EGF) regulates survival of midbrain dopaminergic neurons. J Neural Transm. 2002;109:267–277. [PubMed]
27. Hu WT, Chen-Plotkin A, Arnold SE, et al. Novel CSF biomarkers for Alzheimer's disease and mild cognitive impairment. Acta Neuropathol [PMC free article] [PubMed]